A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC (AXEPT)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01996306 |
Recruitment Status :
Completed
First Posted : November 27, 2013
Last Update Posted : January 8, 2019
|
Sponsor:
Epidemiological and Clinical Research Information Network
Information provided by (Responsible Party):
Epidemiological and Clinical Research Information Network
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | November 20, 2017 |
Actual Study Completion Date : | June 30, 2018 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):